https://www.oncologynurseadvisor.com Sat, 14 Oct 2023 02:39:42 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/development-of-secondary-primary-malignancies-changes-with-disease-stage-and-time-since-diagnosis/ Wed, 02 Oct 2019 20:49:23 +0000 https://www.oncologynurseadvisor.com/?p=68246 The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/evaluating-secondary-malignancy-incidence-and-risk-factors-in-patients-with-follicular-lymphoma/ Thu, 11 Jul 2019 14:00:33 +0000 https://www.hematologyadvisor.com/?p=34078 Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/assessing-patterns-of-survival-in-mantle-cell-lymphoma-following-multiple-relapses/ Tue, 02 Jul 2019 13:00:57 +0000 https://www.hematologyadvisor.com/?p=33202 Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/influence-of-daratumumab-on-quality-of-life-of-patients-with-multiple-myeloma/ Thu, 06 Jun 2019 18:30:03 +0000 https://www.hematologyadvisor.com/?p=32862 Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/improved-outcomes-with-carfilzomib-administered-once-weekly-for-relapsed-refractory-mm/ Mon, 03 Jun 2019 19:28:01 +0000 https://www.hematologyadvisor.com/?p=32774 Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.]]> https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/chronic-myeloid-leukemia/incidence-of-second-malignancies-higher-in-patients-with-cml-compared-with-general-population/ Tue, 21 May 2019 13:30:47 +0000 https://www.hematologyadvisor.com/?p=31434 Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/american-society-of-hematology-ash/ash-annual-meeting-2018/stringent-complete-response-criteria-for-patients-with-multiple-myeloma-may-lack-predictive-value/ Tue, 04 Dec 2018 14:30:00 +0000 https://www.oncologynurseadvisor.com/uncategorized/stringent-complete-response-criteria-for-patients-with-multiple-myeloma-may-lack-predictive-value/ Stringent CR criteria may not predict clinical outcomes for patients with multiple myeloma.]]>